Multiple Sclerosis – Drugs in Development, 2021

Global Markets Direct’s, ‘Multiple Sclerosis – Drugs in Development, 2021’, provides an overview of the Multiple Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis

– The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Multiple Sclerosis therapeutics and enlists all their major and minor projects

– The report assesses Multiple Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

AB Science SA

Abata Therapeutics

AbbVie Inc

Abeome Corp

Abion Inc

Abivax SA

Abreos Biosciences Inc

Accure Therapeutics SL

Aequus Pharmaceuticals Inc

Affectis Pharmaceuticals AG

AgoneX Biopharmaceuticals Inc

Ahead Therapeutics SL

Akaal Pharma Pty Ltd

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

Alpine Immune Sciences Inc

Altheia Science SRL

Amarna Therapeutics BV

Table of Contents

Table of Contents

Introduction

Global Markets Direct Report Coverage

Multiple Sclerosis – Overview

Multiple Sclerosis – Therapeutics Development

Multiple Sclerosis – Therapeutics Assessment

Multiple Sclerosis – Companies Involved in Therapeutics Development

Multiple Sclerosis – Drug Profiles

Multiple Sclerosis – Dormant Projects

Multiple Sclerosis – Discontinued Products

Multiple Sclerosis – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Multiple Sclerosis, 2021 .

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021 .

Number of Products by Stage and Molecule Type, 2021 .

Multiple Sclerosis – Pipeline by 4D Pharma Plc, 2021 .

Multiple Sclerosis – Pipeline by AB Science SA, 2021 .

Multiple Sclerosis – Pipeline by Abata Therapeutics, 2021

Multiple Sclerosis – Pipeline by AbbVie Inc, 2021

Multiple Sclerosis – Pipeline by Abeome Corp, 2021 .

Multiple Sclerosis – Pipeline by Abion Inc, 2021

Multiple Sclerosis – Pipeline by Abivax SA, 2021 .

Multiple Sclerosis – Pipeline by Abreos Biosciences Inc, 2021

Multiple Sclerosis – Pipeline by Accure Therapeutics SL, 2021 .

Multiple Sclerosis – Pipeline by Aequus Pharmaceuticals Inc, 2021

Multiple Sclerosis – Pipeline by Affectis Pharmaceuticals AG, 2021

Multiple Sclerosis – Dormant Projects, 2021

Multiple Sclerosis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Multiple Sclerosis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports